128 related articles for article (PubMed ID: 16396769)
1. Prognostic scoring model based on multi-drug resistance status and cytogenetics in adult patients with acute myeloid leukemia.
Kim DH; Lee NY; Baek JH; Kim JG; Sohn SK; Suh JS; Lee KS; Lee KB
Leuk Lymphoma; 2006 Mar; 47(3):461-7. PubMed ID: 16396769
[TBL] [Abstract][Full Text] [Related]
2. Flt3 internal tandem duplication and P-glycoprotein functionality in 171 patients with acute myeloid leukemia.
Marzac C; Teyssandier I; Calendini O; Perrot JY; Faussat AM; Tang R; Casadevall N; Marie JP; Legrand O
Clin Cancer Res; 2006 Dec; 12(23):7018-24. PubMed ID: 17145823
[TBL] [Abstract][Full Text] [Related]
3. A new prognostic score for patients with acute myeloid leukemia based on cytogenetics and early blast clearance in trials of the German AML Cooperative Group.
Haferlach T; Kern W; Schoch C; Schnittger S; Sauerland MC; Heinecke A; Büchner T; Hiddemann W;
Haematologica; 2004 Apr; 89(4):408-18. PubMed ID: 15075074
[TBL] [Abstract][Full Text] [Related]
4. Prognostic relevance of immunophenotyping in 379 patients with acute myeloid leukemia.
Chang H; Salma F; Yi QL; Patterson B; Brien B; Minden MD
Leuk Res; 2004 Jan; 28(1):43-8. PubMed ID: 14630079
[TBL] [Abstract][Full Text] [Related]
5. Case-control study of multidrug resistance phenotype and response to induction treatment including or not fludarabine in newly diagnosed acute myeloid leukaemia patients.
Malagola M; Damiani D; Martinelli G; Michelutti A; Cesana B; Vivo AD; Piccaluga PP; Ottaviani E; Candoni A; Geromin A; Tiribelli M; Fanin R; Testoni N; Lauria F; Bocchia M; Gobbi M; Pierri I; Zaccaria A; Zuffa E; Mazza P; Priccolo G; Gugliotta L; Bonini A; Visani G; Skert C; Bergonzi C; Roccaro AM; Filí C; Baccarani M; Russo D
Br J Haematol; 2007 Jan; 136(1):87-95. PubMed ID: 17222198
[TBL] [Abstract][Full Text] [Related]
6. The prognostic significance of the expression and function of multidrug resistance transporter proteins in acute myeloid leukemia: studies of the Southwest Oncology Group Leukemia Research Program.
Willman CL
Semin Hematol; 1997 Oct; 34(4 Suppl 5):25-33. PubMed ID: 9408958
[TBL] [Abstract][Full Text] [Related]
7. Parameters for predicting allogeneic PBSCT outcome of acute myeloid leukemia: cytogenetics at presentation versus disease status at transplantation.
Kim DH; Sohn SK; Kim JG; Lee NY; Sung WJ; Baek JH; Suh JS; Lee KS; Lee KB
Ann Hematol; 2005 Jan; 84(1):25-32. PubMed ID: 15349754
[TBL] [Abstract][Full Text] [Related]
8. Multidrug resistance as a potential prognostic indicator in acute myeloid leukemia with normal karyotypes.
Kim DH; Lee NY; Sung WJ; Baek JH; Kim JG; Sohn SK; Suh JS; Lee KS; Lee KB
Acta Haematol; 2005; 114(2):78-83. PubMed ID: 16103629
[TBL] [Abstract][Full Text] [Related]
9. The role of MDR-related proteins in the prognosis of adult acute myeloid leukaemia (AML) with normal karyotype.
Damiani D; Tiribelli M; Raspadori D; Michelutti A; Gozzetti A; Calistri E; Candoni A; Chiarvesio A; Lenoci M; Russo D; Fanin R
Hematol Oncol; 2007 Mar; 25(1):38-43. PubMed ID: 17200981
[TBL] [Abstract][Full Text] [Related]
10. Morphologic dysplasia in de novo acute myeloid leukemia (AML) is related to unfavorable cytogenetics but has no independent prognostic relevance under the conditions of intensive induction therapy: results of a multiparameter analysis from the German AML Cooperative Group studies.
Haferlach T; Schoch C; Löffler H; Gassmann W; Kern W; Schnittger S; Fonatsch C; Ludwig WD; Wuchter C; Schlegelberger B; Staib P; Reichle A; Kubica U; Eimermacher H; Balleisen L; Grüneisen A; Haase D; Aul C; Karow J; Lengfelder E; Wörmann B; Heinecke A; Sauerland MC; Büchner T; Hiddemann W
J Clin Oncol; 2003 Jan; 21(2):256-65. PubMed ID: 12525517
[TBL] [Abstract][Full Text] [Related]
11. Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461.
; Farag SS; Archer KJ; Mrózek K; Ruppert AS; Carroll AJ; Vardiman JW; Pettenati MJ; Baer MR; Qumsiyeh MB; Koduru PR; Ning Y; Mayer RJ; Stone RM; Larson RA; Bloomfield CD
Blood; 2006 Jul; 108(1):63-73. PubMed ID: 16522815
[TBL] [Abstract][Full Text] [Related]
12. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study.
Slovak ML; Kopecky KJ; Cassileth PA; Harrington DH; Theil KS; Mohamed A; Paietta E; Willman CL; Head DR; Rowe JM; Forman SJ; Appelbaum FR
Blood; 2000 Dec; 96(13):4075-83. PubMed ID: 11110676
[TBL] [Abstract][Full Text] [Related]
13. MDR 1 expression is an independent prognostic factor for response and survival in de novo acute myeloid leukaemia.
van den Heuvel-Eibrink MM; van der Holt B; te Boekhorst PA; Pieters R; Schoester M; Löwenberg B; Sonneveld P
Br J Haematol; 1997 Oct; 99(1):76-83. PubMed ID: 9359506
[TBL] [Abstract][Full Text] [Related]
14. MDR1 and MRP1 gene expression are independent predictors for treatment outcome in adult acute myeloid leukaemia.
Schaich M; Soucek S; Thiede C; Ehninger G; Illmer T;
Br J Haematol; 2005 Feb; 128(3):324-32. PubMed ID: 15667534
[TBL] [Abstract][Full Text] [Related]
15. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype.
Bloomfield CD; Lawrence D; Byrd JC; Carroll A; Pettenati MJ; Tantravahi R; Patil SR; Davey FR; Berg DT; Schiffer CA; Arthur DC; Mayer RJ
Cancer Res; 1998 Sep; 58(18):4173-9. PubMed ID: 9751631
[TBL] [Abstract][Full Text] [Related]
16. Association of specific cytogenetic aberrations with mdr1 gene expression in adult myeloid leukemia and its implication in treatment outcome.
Schaich M; Harbich-Brutscher E; Pascheberg U; Mohr B; Soucek S; Ehninger G; Illmer T
Haematologica; 2002 May; 87(5):455-64. PubMed ID: 12010657
[TBL] [Abstract][Full Text] [Related]
17. The prognostic value of Bcl-XL gene expression for remission induction is influenced by cytogenetics in adult acute myeloid leukemia.
Schaich M; Illmer T; Seitz G; Mohr B; Schäkel U; Beck JF; Ehninger G
Haematologica; 2001 May; 86(5):470-7. PubMed ID: 11410409
[TBL] [Abstract][Full Text] [Related]
18. Abnormal cytogenetics at date of morphologic complete remission predicts short overall and disease-free survival, and higher relapse rate in adult acute myeloid leukemia: results from cancer and leukemia group B study 8461.
Marcucci G; Mrózek K; Ruppert AS; Archer KJ; Pettenati MJ; Heerema NA; Carroll AJ; Koduru PR; Kolitz JE; Sterling LJ; Edwards CG; Anastasi J; Larson RA; Bloomfield CD
J Clin Oncol; 2004 Jun; 22(12):2410-8. PubMed ID: 15197203
[TBL] [Abstract][Full Text] [Related]
19. Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML.
Schoch C; Kern W; Schnittger S; Hiddemann W; Haferlach T
Leukemia; 2004 Jan; 18(1):120-5. PubMed ID: 14586477
[TBL] [Abstract][Full Text] [Related]
20. Multidrug resistance gene expression in acute myeloid leukemia: major prognosis significance for in vivo drug resistance to induction treatment.
Hunault M; Zhou D; Delmer A; Ramond S; Viguié F; Cadiou M; Perrot JY; Levy V; Rio B; Cymbalista F; Zittoun R; Marie JP
Ann Hematol; 1997 Feb; 74(2):65-71. PubMed ID: 9063375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
